- $1.67bn
- $1.43bn
- $62.90m
Brief: Omega Fund V LP Reports 3.9% Stake In Nuvation Bio As Of Sept 4, 2024 Versus 6.9% As Of April 5, 2022 - SEC Filing
Brief: Xiangmin Cui Reports 8.0% Stake In Nuvation Bio As Of September 3- SEC Filing
Brief: Nuvation Bio Q2 EPS USD -1.89
Nuvation Bio Inc expected to post a loss of 6 cents a share - Earnings Preview
Brief: Nuvation Bio Announces Updates And Upcoming Presentations For Its ROS1 Inhibitor, Taletrectinib
I Study Of Its Investigational Ros1 Inhibitor, Taletrectinib
Nuvation Bio Inc expected to post a loss of 10 cents a share - Earnings Preview
Brief: Nuvation Bio Completes Acquisition Of Anheart Therapeutics
Brief: Oncology Firm Nuvation Bio Appoints Former Madrigal Pharmaceuticals Exec Colleen Sjogren As Chief Commercial Officer
U.S. RESEARCH ROUNDUP-Acuity Brands, CSG Systems International, Nuvation Bio
U.S. STOCKS ON THE MOVE-Nuvation Bio, Seagate, AppFolio
U.S. STOCKS ON THE MOVE-Reddit, CONSOL Energy, Nuvation Bio
Nuvation Bio rises on deal to become commercial organization by 2025
Brief: Nuvation Bio To Acquire Anheart Therapeutics In All-Stock Transaction
Brief: Nuvation Bio Doses First Patient In Phase 1/2 Study Of NUV-1511
Brief: Nuvation Bio Q4 EPS USD -0.06
Brief: Nuvation Bio Announces FDA Clearance Of Investigational New Drug Application For NUV-1511
Nuvation Bio Inc reports results for the quarter ended in September - Earnings Summary
Brief: Nuvation Bio Q3 EPS USD -0.09